Folate Metabolism in Colorectal Cancer Reveals Links Between Clinical and Immune Traits, Identifying CYP26A1 as a Target
Source check: Source checked. Not independent scientific confirmation.
Finding: A folate-metabolism gene score stratifies colorectal-cancer prognosis/immune traits, and CYP26A1 is tested as a candidate target. The reviewed source supports this bounded result; external generalization, causal effects, and sustained operational impact remain unestablished where the source reports retrospective or internal evaluation.
Technology: TCGA and external clinical cohorts validate the risk score; in-vitro experiments test CYP26A1 effects on cancer-cell proliferation, migration and invasion.
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- TCGA and external clinical cohorts validate the risk score; in-vitro experiments test CYP26A1 effects on cancer-cell proliferation, migration and invasion.
- Test and result
- A folate-metabolism gene score stratifies colorectal-cancer prognosis/immune traits, and CYP26A1 is tested as a candidate target.
- Limitation / still unknown
- Cell evidence and retrospective cohorts do not establish clinical treatment efficacy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.researchsquare.com/article/rs-5647525/v1.pdf?c=1751541245000
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.